OpenNashPodcasts

Topic

Bristol Myers Squibb

8 facts from 6 episodes, in date order. These are what speakers said on the shows, each linked to the moment it was said. They aren't independently verified.

2012

On February 15, 2012, Bristol-Myers Squibb CEO Lamberto Andreotti offered $22 a share for Amylin, which the board rejected without disclosing it.

“He's calling with an offer to Amylin, $22 a share to buy the whole company. At the time, Amylin is trading around $14 to $16 a share.”

Matthew Pech · Episode #1: Amylin Pharmaceuticals, 1:09:28

Undated

Nick Hellman was recruited to Bristol-Myers Squibb to work on an early antiretroviral drug, which took the couple to Connecticut.

“And then Nick got recruited to Bristol-Myers Squibb to work on D14, one of the first antiretroviral drugs.”

Sue Desmond-Hellmann · Ep95: Sue Desmond-Hellmann on Becoming a Biotech Leader, 0:37:41

Undated

Bristol Myers Squibb chose to pursue the first ALS target as a small molecule, while Insitro advances it as an intrathecal oligonucleotide at its own cost.

“BMS elected to pursue the first of those targets, ALS-1, as a small molecule.”

Daphne Koller · Ep213: Daphne Koller on The Moment in AI Drug Discovery, 0:47:07

Episodes